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Abstract
 
The role of CD8
 
1
 
 T lymphocytes in controlling replication of live, attenuated simian immu-
nodeficiency virus (SIV) was investigated as part of a vaccine study to examine the correlates of
 
protection in the SIV/rhesus macaque model. Rhesus macaques immunized for 
 
.
 
2 yr with
nef-deleted SIV (SIVmac239
 
D
 
nef) and protected from challenge with pathogenic SIVmac251
were treated with anti-CD8 antibody (OKT8F) to deplete CD8
 
1
 
 T cells in vivo. The effects of
CD8 depletion on viral load were measured using a novel quantitative assay based on real-time
polymerase chain reaction using molecular beacons. This assay allows simultaneous detection of
both the vaccine strain and the challenge virus in the same sample, enabling direct quantifica-
tion of changes in each viral population. Our results show that CD8
 
1
 
 T cells were depleted
within 1 h after administration of OKT8F, and were reduced by as much as 99% in the periph-
eral blood. CD8
 
1
 
 T cell depletion was associated with a 1–2 log increase in SIVmac239
 
D
 
nef
plasma viremia. Control of SIVmac239
 
D
 
nef replication was temporally associated with the re-
covery of CD8
 
1
 
 T cells between days 8 and 10. The challenge virus, SIVmac251, was not de-
tectable in either the plasma or lymph nodes after depletion of CD8
 
1
 
 T cells. Overall, our re-
sults indicate that CD8
 
1
 
 T cells play an important role in controlling replication of live,
attenuated SIV in vivo.
Key words: simian immunodeficiency virus • live attenuated vaccine • OKT8F • CD8
 
1
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Introduction
 
A distinguishing feature of live, attenuated vaccines is the
persistence of the vaccine strain in the immunized host.
Rhesus macaques immunized with nef-deleted simian im-
 
munodeficiency virus (SIVmac239
 
D
 
nef)
 
1
 
 have a peak of
viremia (10
 
5
 
–10
 
7
 
 RNA copies/ml) in the first few weeks
after infection, and virus often remains detectable at low
levels for years in peripheral blood and LNs. In most cases,
virus replication is well controlled and infected animals re-
main clinically healthy. However, in some instances, infec-
tion with live, attenuated SIV leads to high levels of vire-
mia and disease progression in both infant and adult
macaques (1–4), raising questions as to the safety of these
candidate vaccines. Although vigorous immune responses
are induced after immunization with live, attenuated SIV
(for a review, see reference 5), the mechanisms involved in
controlling virus replication in the host are unknown.
 
Despite persistence of the vaccine strain, rhesus macaques
immunized with live, attenuated SIV are protected from
pathogenic infection with wild-type SIV (3, 6–14). Be-
cause of the robust protection provided by this vaccine
model, immune responses induced as a result of immuniza-
tion have been investigated as possible correlates of protec-
tion (for a review, see reference 5). Several studies have
demonstrated the presence of antibodies against SIV pro-
teins in immunized macaques (3, 12, 15–19). However, no
 
Address correspondence to Ruth I. Connor, Aaron Diamond AIDS Re-
search Center, 455 First Ave., 7th Fl., New York, NY 10016. Phone:
212-448-5040; Fax: 212-725-1126; E-mail: rconnor@adarc.org
 
1
 
Abbreviations used in this paper:
 
 AID, animal infectious dose; CCR5,
CC chemokine receptor 5; nt, nucleotide(s); RT, reverse transcription;
 
SIV, simian immunodeficiency virus; SIVmac239
 
D
 
nef, nef-deleted infec-
tious clone of SIV; TCID
 
50
 
, 50% tissue culture infective dose. 
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correlation has been found between protection from
pathogenic SIV infection and the ability of anti-SIV anti-
bodies to neutralize the challenge strain (3, 12, 13, 17, 18),
nor could protection be conferred by the transfer of im-
mune serum from protected macaques (20). Induction of
SIV-specific CTLs has also been documented in peripheral
blood (21, 22) and tissues (23) of rhesus macaques immu-
nized with live, attenuated SIV, suggesting that cellular im-
mune responses play a key role in protection.
Several lines of evidence support the concept that CTLs
are critical in controlling virus replication. In vitro assess-
ments of CTL activity have demonstrated a temporal rela-
tionship between the induction of CTLs and suppression of
HIV-1 (24), and SIV (25, 26) replication during primary
infection. Low viral loads in HIV-1–infected long-term
nonprogressors (27, 28) and in rhesus macaques infected
with live, attenuated SIV (22) have been associated with
high levels of virus-specific CTL activity. Recently, cellular
immune responses have been shown to directly control
replication of wild-type SIV (29, 30) and simian/human
immunodeficiency virus (SHIV) (31) in vivo during acute
and chronic infection.
Whether CD8
 
1
 
 T lymphocytes are involved in control-
ling replication of SIVmac239
 
D
 
nef in vivo and whether
these cells play a direct role in mediating protection from
pathogenic SIV challenge are not known. Studies aimed at
in vivo depletion of CD8
 
1
 
 T cells are often complicated by
difficulties in affecting complete and sustained depletion of
cells from the periphery and LNs (32). Moreover, in the
setting of vaccine studies, in vivo depletion of CD8
 
1
 
 T
cells often necessitates the use of quantitative assays capable
of discriminating between the vaccine and challenge strains.
In this study, we investigated the effect of in vivo deple-
tion of CD8
 
1
 
 T cells on virus replication in rhesus
macaques immunized with SIVmac239
 
D
 
nef. A total of
six adult macaques were studied: three infected with
 
SIVmac239
 
D
 
nef, and three immunized with SIVmac239-
 
D
 
nef and challenged with pathogenic SIVmac251. To dis-
tinguish between the vaccine strain (SIVmac239
 
D
 
nef) and
the challenge virus (SIVmac251), a novel quantitative assay
was developed based on the use of real-time PCR and mo-
lecular beacons (33–35). Our results indicate that CD8
 
1
 
 T
cells play an important role in controlling replication of
SIVmac239
 
D
 
nef in immunized macaques.
 
Materials and Methods
 
Immunization of Rhesus Macaques.
 
Six adult rhesus macaques
(
 
Macaca mulatta
 
)
 
 
 
were immunized with SIVmac239
 
D
 
nef (pro-
vided by Dr. Ronald Desrosiers, New England Regional Primate
Center, Harvard Medical School, Southborough, MA) by intra-
venous administration of 4 
 
3
 
 10
 
3
 
 50% tissue culture infective
doses (TCID
 
50
 
) as described previously (3) (Table I). All six
macaques became infected on the basis of detection of
SIVmac239
 
D
 
nef RNA in plasma (3). Three of these animals were
then intravenously challenged at 15 or 25 wk after immunization
with 10 animal infectious doses (AID) of uncloned SIVmac251
(provided by Dr. Desrosiers). The immunized and challenged
macaques were monitored for the presence of SIVmac239
 
D
 
nef
and SIVmac251 by nested DNA PCR for 2 yr. During this time,
there was no evidence of the challenge virus in PBMC samples
from the peripheral blood (Metzner, K.J., unpublished data), sug-
gesting that the macaques were protected from challenge.
 
Depletion of CD8
 
1
 
 T Cells In Vivo.
 
CD8
 
1
 
 T cells were de-
pleted in vivo by administration of the anti-CD8 antibody,
OKT8F (provided by K. Demarest and T. Mercolino, The R.W.
Johnson Pharmaceutical Research Institute, Raritan, NJ). Four
macaques received OKT8F (1496, 1502, 1518, and 1520),
whereas the remaining two macaques (1506 and 1522) were
given an isotype-matched control antibody, P1.17 (TIB-10;
American Type Culture Collection). All animal protocols were
approved by the Institutional Animal Care and Use Committee at
the Tulane Regional Primate Research Center.
 
Table I.
 
Baseline Characteristics of Rhesus Macaques before CD8
 
1
 
 T Cell Depletion
 
Lymphocyte count
 
*
 
SIVmac239
 
D
 
nef viral load
Macaque Immunized
 
‡
 
Challenged
 
§
 
CD4
 
1
 
 T cells CD8
 
1
 
 T cells
Chiron 
bDNA plasma
Real-time 
PCR plasma
 
i
 
Real-time PCR 
PBMC
 
i
 
cells/mm
 
3
 
cells/mm
 
3
 
RNA copies/ml RNA copies/ml copies/10
 
6
 
 PBMCs
 
1496/AT41
 
¶
 
SIVmac239
 
D
 
nef SIVmac251 581 
 
6 
 
193 1,317 
 
6 
 
254
 
,
 
10
 
4
 
1.1 
 
3
 
 10
 
3
 
,
 
50
1502/AT44 SIVmac239
 
D
 
nef SIVmac251 1,408 
 
6 
 
218 895 
 
6 
 
145
 
,
 
10
 
4
 
2.5 
 
3
 
 10
 
3
 
,
 
50
1506/AT45 SIVmac239
 
D
 
nef SIVmac251 664 
 
6 
 
141 519 
 
6 
 
118
 
,
 
10
 
4
 
1.3 
 
3
 
 10
 
3
 
,
 
50
1518/AT49 SIVmac239
 
D
 
nef – 692 
 
6 
 
199 738 
 
6 
 
153
 
,
 
10
 
4
 
0.2 
 
3
 
 10
 
3
 
,
 
50
1520/AT50 SIVmac239
 
D
 
nef – 989 
 
6 
 
97 1,709 
 
6 
 
427
 
,
 
10
 
4
 
1.8 
 
3
 
 10
 
3
 
,
 
50
1522/AT51 SIVmac239
 
D
 
nef – 695 
 
6 
 
98 1,288 
 
6 412 ,104 6.1 3 103 ,50
*Represent the mean 6 SD of days 27, 25, 21, and 0 before administration of anti-CD8 or control antibody.
‡Represent data collected 1 d before administration of anti-CD8 or control antibody.
§Rhesus macaques were immunized with 2 3 104 TCID50 of SIVmac239Dnef on August 22, 1996.
iMacaques 1469, 1502, and 1506 were challenged with 10 AID of SIVmac251 at 15 or 25 wk after immunization.
¶Designation used at the Tulane Regional Primate Research Center.1923 Metzner et al.
Macaques were anesthetized with 10 mg/kg ketamine-HCl,
then either OKT8F or P1.17 were given intravenously at 2 mg/
kg/d for three consecutive days. 3–5 ml of peripheral blood were
obtained frequently before and after antibody administration. In-
guinal and axillary LN biopsies were obtained at baseline (day
21) and on days 7 and 14 after antibody administration. Each
node was sectioned into triplicate samples and stored frozen at
2808C until processing.
Phenotypic Analysis of Cell Subsets. Four-color flow cytomet-
ric analyses of whole blood samples were performed to monitor
changes in T cell populations. In brief, 100 ml aliquots of whole
blood were incubated with respective antibodies for 30 min at
48C, then washed twice with PBS containing 2% FCS. The
RBCs were lysed with FACS™ Lysing Solution (Becton Dickin-
son) and washed twice with PBS, followed by further washes and
resuspension in 2% formaldehyde (Tousimis Research Corpora-
tion) before analysis on a FACSCalibur™ flow cytometer (Becton
Dickinson). The antibodies used in the study were RhCD3-FITC
(Immunotech), CD3-PE (BD PharMingen), CD4-allophycocya-
nin (APC) (Exalpha Biologicals, Inc.), CD8-peridinine chloro-
phyll protein (PerCP) (Becton Dickinson), CD16-FITC (Becton
Dickinson), CD20-PE (Becton Dickinson), and control antibod-
ies IgG1-FITC, IgG1-PE, IgG1-PerCP, and IgG1-APC (Caltag).
The results were analyzed using CELLQuest™ software by first
gating on small lymphocytes, then displaying the subset of cells on
a two-dimensional density plot. The number of CD41 and
CD81 T lymphocytes was determined using the Becton Dickin-
son TruCount™ method. The total number of T cells was deter-
mined (CD4 and CD8) and the percentage of lymphocyte subsets
in the blood was assessed by staining PBMCs with directly conju-
gated antibodies, followed by FACS® analysis. The number of
cells in each subset, e.g., CD161 cells, was then calculated using
the following formula: the number of CD161 cells 5 (% CD161
cells/% CD31 cells) 3 the number of CD31 cells.
Extraction of RNA and DNA from Plasma, PBMCs, and LNs.
Plasma samples collected from blood in EDTA anticoagulant
were centrifuged at 2,000 g for 5 min to pellet cell debris. SIV
RNA was purified from cell-free plasma (500 ml) using the
QIAamp Viral RNA Mini kit (Qiagen) according to the manu-
facturer’s instructions for large sample volumes. Genomic DNA
was extracted from 1–2 3 106 PBMCs using the QIAamp DNA
Mini kit (Qiagen) following the manufacturer’s protocol with the
exception that 60 ml of buffer was used to elute the DNA. To ex-
tract RNA from LNs, tissues were thawed, disrupted with a scal-
pel, and homogenized using a QIAshredder (Qiagen). RNA was
isolated by using the RNeasy Mini kit (Qiagen) according to the
manufacturer’s instructions.
Differential Quantification of SIVmac239Dnef and SIVmac251 Vi-
ral and Proviral Load. Reverse transcription (RT) with viral
RNA from plasma or LN samples was performed in MicroAmp
optical 96-well reaction plates (PE Biosystems). Viral RNA (10
ml) was added to 0.7 mM of a gene-specific primer recognizing
either SIVmac239Dnef (59-CTTCCAGTCCC-39, nucleotide
[nt] 9467; 36) or SIVmac251 (59-CTCATCTATATCATCC-39,
nt 9352; 36), and incubated at 808C for 5 min to dissolve second-
ary structures. The plate was then immediately placed on ice for
at least 2 min. RT reactions consisted of PCR buffer II (PE Bio-
systems), 3 mM MgCl2, 1 mM dNTPs (GIBCO BRL), 10 mM
dithiothreitol, 20 U RNase inhibitor (Roche Molecular Bio-
chemicals), and 40 U SuperScript II RNase H2 reverse tran-
scriptase (GIBCO BRL) in a final volume of 30 ml. The reactions
were incubated at 428C for 50 min followed by inactivation at
708C for 15 min.
Amplification of SIVmac239Dnef cDNA was performed using
a hairpin-shaped PCR primer that hybridizes across the junction
of the nef deletion (see Fig. 1 A). Use of this primer promotes in-
dependent amplification of SIVmac239Dnef regardless of the
presence of SIVmac251 in the same plasma sample. A molecular
beacon was used for detection of amplicons in real-time PCR.
PCR reactions for amplification of SIVmac239Dnef consisted of
30  ml of cDNA products, 13 ROX-PCR buffer, 3.5 mM
MgCl2, 0.4 mM upstream primer nef1 59-GGGAGACTCT-
TAGGAGAGGTGGAAGATGG-39 (nt 9161; 36), 0.4 mM hair-
pin-shaped downstream primer hs Dnef 59-GGGACAGC-
CTTTTCTTTTATAAAATGAGACCTGTCCC-39  (nt 9449;
36) (complementary arm sequences that form the stem are under-
lined), 0.4 mM molecular beacon mb Dnef FAM-59-CACTC-
CCCAGGAGGATTAGACAAGGGAGTG-39-DABCYL (nt
9204; 36), and 2.5 U AmpliTaq Gold DNA polymerase (PE Bio-
systems) in a final volume of 50 ml.
For amplification of SIVmac251 cDNA, a wild-type, nef-spe-
cific, hairpin-shaped downstream primer was used, which hybridizes
to the deleted region of SIVmac239Dnef (Fig. 1 B) and allows
amplification of SIVmac251 independently of SIVmac239Dnef in
the same plasma sample. PCR reactions for amplification of
SIVmac251 cDNA contained the reagents described above, with
the substitution of 0.4 mM wild-type hairpin-shaped downstream
primer hs wt nef 59-CTCCATGGTCTTCAGCTGGGTTTCT-
CCATGGAG-39 (nt 9303; 36), and 0.4 mM molecular beacon
mb wt nef FAM-59-CACTCCCTAGGAGGATTAGACAAG-
GGAGTG-39-DABCYL (nt 9204; 36).
60 cycles of amplification (948C for 15 s, 608C for 30 s, and
728C for 30 s) were performed in a 7700 Prism spectrofluoromet-
ric thermal cycler (PE Biosystems). In cases of undetectable
SIVmac251, an additional real-time amplification was performed
using 0.4 mM upstream primer nef3 59-TAGGAGAGGTG-
GAAGATGGATMCTCGC-39 (nt 9171; 36), 0.4 mM down-
stream primer wt nef2 59-GCTAATTTTTCTCTCTCT-
TCAGCTGGG-39 (nt 9318; 36), and 0.4 mM molecular beacon
mb wt nef. Proviral SIVmac239Dnef and SIVmac251 DNA were
measured by real-time PCR as described above using 5 ml ge-
nomic DNA extracted from PBMCs.
Duplicates of in vitro RNA transcripts or DNA quantified by
OD260 measurements were used as standards for each experiment
and were serially diluted from 107 to 20 or 10 copies per reaction,
respectively. Viral RNA or genomic DNA samples were also
tested in duplicate. As a control for potential DNA contamina-
tion of viral RNA, an additional reaction was tested in real-time
PCR without the addition of reverse transcriptase. Copy num-
bers were calculated by interpolation of the experimentally deter-
mined threshold cycle for the test specimen onto the control
standard regression curve (37). Both real-time RT-PCR assays
have a detection limit of 50 SIV RNA copies/mL with a linear
dynamic range of .5 logs. RNA copy numbers in LNs were
normalized per 1 mg of total RNA.
Proviral DNA copy numbers were calculated per 106 genomic
equivalents measured by real-time amplification of the single-
copy CC chemokine receptor 5 (CCR5) gene (Kostrikis, L.G.,
and D.D. Ho, unpublished data). In brief, PCR reactions consist-
ing of 5 ml genomic DNA, 13 ROX-PCR buffer, 3.5 mM
MgCl2, 1 mM dNTPs (GIBCO BRL), 0.4 mM upstream primer
rhesus (rh) CCR5 59-GAGAAGGTCTTCATTACACCTGC-39
(nt 750; sequence data available from EMBL/GenBank/DDBJ
under accession no. MMU77672), 0.4 mM downstream primer rh
CCR5 d 59-GATTCCCGAGTAGCAGATGACC-39 (nt 889),
0.4 mM molecular beacon mb rh CCR5 FAM-59-CCGGTCT-1924 Suppression of Live, Attenuated SIV In Vivo by CD81 T Cells
GAAAATTCTTCCAGAATTGATACTGACCGG-39-DABCYL
(nt 819), and 2.5 U AmpliTaq Gold DNA polymerase (PE Bio-
systems) were performed in a final volume of 50 ml.
Results
The six macaques described in this study were previously
immunized with a live, attenuated strain of SIV (SIVmac239-
Dnef). Three of the six were subsequently challenged with
pathogenic SIVmac251 (1496, 1502, and 1506), and all an-
imals were monitored for SIV RNA in plasma and for
changes in CD41 and CD81 T cell counts over a follow-
up period of .2 yr. At the initiation of the current study,
all macaques were clinically healthy, with CD41 and
CD81 T cell counts in the normal range and undetectable
plasma viremia as determined by the bDNA assay (,104
SIV RNA copies/ml of plasma; Chiron Corporation [38])
(Table I).
To evaluate changes in viral load as a result of in vivo
CD81 T cell depletion, a novel assay was first developed to
allow simultaneous quantification of both the vaccine strain
(SIVmac239Dnef) and the challenge virus (SIVmac251) in
the same sample. This assay is based on real-time PCR us-
ing molecular beacons and primers hybridizing within and
flanking the 182-bp deleted region of nef, and allows for
discrimination of nef-deleted and wild-type SIV nef genes
(Fig. 1, A and B). Initial evaluation of standard SIV RNA
preparations defined a dynamic range of .5 logs for both
nef-deleted and wild-type RNA when analyzed separately.
The discriminatory ability of the assays was tested in re-
ciprocal mixing experiments by adding to a serial dilution
(108 to 10 copies) of either SIVmac239Dnef or SIVmac251
RNA or DNA standard, 108 copies of noncomplimentary
RNA or DNA. Amplifications were performed and results
were compared with threshold cycles from PCR reactions
performed without the addition of noncomplimentary viral
RNA or DNA. Results from these experiments indicate
that the assay for amplification of SIVmac239Dnef has a dis-
criminatory ability of 1 copy of SIVmac239Dnef/106 copies
of SIVmac251, whereas the amplification of SIVmac251
has a discriminatory ability of 1/107 (Fig. 2, A and B).
Longitudinal plasma samples obtained from a rhesus
macaque immunized with SIVmac239Dnef but not pro-
tected from SIVmac251 challenge were then tested to de-
termine the sensitivity and discriminatory ability of the as-
say under more biologically relevant conditions. The results
demonstrate detection of both SIVmac239Dnef and
SIVmac251 in the same plasma sample with a sensitivity of
$50 SIV RNA copies/ml, and document a decline in
SIVmac239Dnef replication that occurred temporally with
an increase in replication of SIVmac251 (Fig. 2 C).
In further experiments, plasma samples from an unre-
lated rhesus macaque infected with wild-type SIV were
also quantified in parallel using either real-time PCR or the
Chiron bDNA assay, and the results were found to be
highly similar (within threefold; data not shown), providing
a basis for comparison with other quantitative SIV studies,
including our previous report (3).
Using the real-time PCR assay to monitor changes in vi-
ral load, the anti-CD8 antibody OKT8F was administered
to 4/6 rhesus macaques (1496, 1502, 1518, and 1520) at a
concentration of 2 mg/kg/d for three consecutive days.
The two remaining macaques (1506 and 1522) received an
isotype-matched control antibody, P1.17. Blood samples
taken at frequent intervals before and after administration
of the antibodies were assayed to monitor changes in
CD81 T cells and viral load (Fig. 3). Within 1 h after ad-
ministration of the first dose of antibody, CD81 T cells de-
creased in the peripheral blood by an average of 99% (from
a mean of 1,151 6 428 to 0 cells/ml) in the four macaques
receiving OKT8F, whereas the CD81 T cell counts re-
mained stable in the two macaques receiving the control
antibody (1506 and 1522). In error, OKT8F was given at
the second injection to one of the control macaques
(1522), resulting in a similar, rapid depletion of CD81 T
cells (Fig. 3 F). To evaluate the effect of a single dose of
OKT8F, the control antibody was then administered to
macaque 1522 for the third injection. For the four
macaques receiving three doses of OKT8F, the number of
CD81 T cells remained low for 8–9 d, and began to re-
Figure 1. Scheme of differential amplification. (A) Amplification of
SIVmac239Dnef. A linearized upstream primer (nef1) and hairpin-shaped
primer (hs Dnef) were used to amplify a 106-bp amplicon. hs Dnef hy-
bridizes across the junction of the deletion in nef, allowing amplification
of SIVmac239Dnef in the presence of SIVmac251. A molecular beacon
(mb Dnef) was used for detection of amplicons. (B) Amplification of
SIVmac251. A linearized primer (nef1) and hairpin-shaped oligonucle-
otide (hs wt nef) were used to amplify a fragment of 142 bp. An addi-
tional PCR was performed using linearized oligonucleotides (nef3 and wt
nef2), which amplify a fragment of 157 bp. Amplicons were detected us-
ing the molecular beacon (mb wt nef).1925 Metzner et al.
cover in all animals by day 10. A slightly more rapid recov-
ery of CD81 T cells, occurring on day 8, was observed for
the macaque receiving one dose of OKT8F, suggesting a
less sustained depletion.
Concomitant with the decrease in peripheral blood
CD81 T cells was a dramatic increase in the levels of SIV-
mac239Dnef in plasma, which occurred in 5/5 macaques
receiving OKT8F antibody. Viral loads at baseline were low
in all immunized macaques (0.22–6.1 3 103 SIV RNA
copies/ml), but increased by a minimum of 1–2 logs after
CD81 T cell depletion. Viremia reached a mean peak value
of 1.7 3 105 SIV RNA copies/ml (0.067–6.4 3 105 cop-
ies/ml) between days 1 and 8 after antibody administration.
Moreover, the decrease in SIVmac239Dnef viremia was
temporally associated with recovery of the CD81 T cell
population in all macaques. Although fluctuations in both
CD81 T cells and viral load occurred in the one macaque
receiving three doses of the control antibody, there was no
clear temporal association between these changes and ad-
ministration of the antibody (Fig. 3 C), similar to what has
been observed using the same control antibody in rhesus
macaques chronically infected with SIV (29).
SIVmac239Dnef proviral DNA at baseline was low or
undetectable (,50 copies/106 genomic equivalents) in
rhesus macaques receiving OKT8F and increased by 0.6–2
logs after administration of OKT8F. Interestingly, the in-
crease in SIVmac239Dnef proviral DNA occurred 1–3 d
after the increase of viral RNA in plasma. Peak values for
proviral DNA ranged from 3 3 102 to 3.1 3 104 copies/
106 genomic equivalents. A decrease of proviral DNA was
temporally associated with the increase of CD81 T cells.
Changes in SIVmac239Dnef proviral load in rhesus
macaque 1506 were not associated with administration of
the control antibody (Fig 3 C).
Simultaneous quantification of SIVmac239Dnef and
SIVmac251 was carried out using plasma and PBMC sam-
Figure 2. (A) Discriminatory ability of real-time PCR
for differential amplification. Amplifications of SIVmac251
were performed using a serial dilution of SIVmac251 DNA
standard with (s) and without (h) the addition of 108
copies of noncomplimentary SIVmac239Dnef DNA stan-
dard. Mean values of reactions performed in duplicate are
shown. The dotted and solid lines indicate the linear stan-
dard curves as results of amplifications with and without
the addition of noncomplimentary DNA, respectively. (B)
Amplifications of SIVmac239Dnef were performed using a
serial dilution of SIVmac239Dnef DNA standard with (s)
and without (h) the addition of 108 copies of noncompli-
mentary SIVmac251 DNA standard. The linear standard
curve for amplification of SIVmac239Dnef DNA alone is
shown in black. The gray section indicates the area where the ratio of copies of SIVmac239Dnef to copies of
SIVmac251 is $1/106. (C) Measurement of SIV RNA in plasma after immunization with SIVmac239Dnef
and challenge with SIVmac251. Rhesus macaque 1510 was immunized with SIVmac239Dnef on day 0
(black arrow) and then challenged with SIVmac251 at 25 wk (white arrow). SIVmac239Dnef RNA (d) and
SIVmac251 RNA (j) in plasma were quantified using real-time PCR for differential amplification. The
limit of sensitivity of the viral load assay is indicated by the dotted line.
Figure 3. Changes in viral load af-
ter in vivo depletion of CD81 T
cells. SIV RNA in plasma and SIV
proviral DNA in PBMCs were deter-
mined for each sample in duplicate by
real-time PCR and differential ampli-
fication. SIV proviral DNA data were
normalized per 106 genomic equiva-
lents measured of the single-copy
gene CCR5. Data are shown for
CD81 T cells (d), SIVmac239Dnef
RNA (j), and SIVmac239Dnef pro-
viral DNA (h). SIVmac251 RNA or
DNA were not detectable. Adminis-
trations of OKT8F (black arrows) or
the control antibody P1.17 (white ar-
rows) were performed on days 0, 1,
and 2. The limit of sensitivity of the
viral load assay is indicated by the
dotted line.1926 Suppression of Live, Attenuated SIV In Vivo by CD81 T Cells
ples from the three macaques that were immunized and
challenged (1496, 1502, and 1506; Table I). In an earlier
study using conventional DNA PCR, we were unable to
detect wild-type nef sequences in PBMCs from these
macaques over a period of 2 yr after challenge (Connor,
R., unpublished data). Before depletion of CD81 T cells in
vivo, baseline samples were assayed by real-time PCR and
SIVmac251 RNA was not detected. After administration of
either the anti-CD8 (1496, 1502) or control antibody
(1506), SIVmac251 remained undetectable in plasma and
PBMCs for the duration of CD81 T cell depletion (data
not shown).
We could not rule out the possibility of low level replica-
tion of SIVmac251 in tissues such as LNs, which may have
been below threshold levels of detection in the peripheral
blood. To investigate this possibility, LN biopsies collected
at baseline (day 21) and on days 7 and 14 after antibody
administration were assayed for the presence of SIV-
mac239Dnef and SIVmac251 RNA. Our results indicate
that SIVmac239Dnef RNA in the LNs at baseline ranged
from 2.3 3 101 to 2.1 3 104 RNA copies/1 mg total RNA
(mean 5.5 3 103 SIV RNA copies/1 mg total RNA) among
the six immunized macaques (Fig. 4). On day 7 after
OKT8F administration, SIVmac239Dnef increased by 0.6–3
logs (mean 5.6 3 104 RNA copies/1 mg total RNA). In
three rhesus macaques, viral loads decreased at day 14 (mean
2.2 3 104 RNA copies/1 mg total RNA), but were still
higher than baseline. Viral RNA values in LN samples from
rhesus macaque 1518 were 2.5 3 103 at day 7 and 3.6 3
103 RNA copies/1 mg total RNA at day 14. The macaque
receiving control antibody (1506) had no significant change
in viral RNA in LNs (Fig. 4). RNA from the challenge vi-
rus, SIVmac251, was below the limit of detection (,10
RNA copies/1 mg total RNA) in all LN samples (Fig. 4).
Our previous work has shown that the depletion of
CD81 T cells is accompanied by a reduction in CD41 T
cells in all animals receiving OKT8F antibody (29), sug-
gesting that OKT8F may lead to nonspecific depletion of
other cell subsets in the lymphoid system. In this study, in
addition to confirming the previously observed depletion
of CD41 T cells (see Fig. 6, A and B), we also examined
changes in B cells expressing the CD20 marker and lym-
phocytes expressing the CD16 surface antigen in the
SIVmac239Dnef-immunized macaques (Fig. 5). Our find-
ings demonstrate no consistent changes in the CD201 lym-
phocyte population as a result of administration of OKT8F
antibody, although an increase in CD201 cells occurred in
four macaques after the first injection but was not sustained
(data not shown).
When changes in CD161 cells were followed longitudi-
nally in all macaques, we observed a partial depletion of cell
numbers immediately after administration of OKT8F, with
variable recovery of the cells over the next 2–21 d (Fig. 6,
C and D). Interestingly, similar decreases in CD161 lym-
phocytes were also observed after administration of the
control antibody, P1.17, to control macaque 1506 (Fig. 6
D), suggesting a nonspecific effect of the antibodies on
CD161 cells.
Evaluating more closely the rate of recovery of CD81 T
cells beginning 7–9 d after challenge, we found that the
macaques segregate into two groups: those with a rapid re-
covery (group A) and those with a twofold slower recovery
rate (group B) (Table II). We expressed the rate of CD81 T
cell recovery mathematically using the logistic growth law
(39), which states that the rate of recovery depends on the
T cell count and slows as the T cell count reaches some
maximum, denoted Tmax. The equation for logistic growth
Figure 4. SIVmac239Dnef RNA in LNs. SIV copy number was deter-
mined for duplicate samples by real-time PCR and differential amplifica-
tion, and the data were normalized per 1 mg of total RNA. The mean of
duplicates as well as the geometric mean are shown for all monkeys re-
ceiving OKT8F (black arrows): 1496 (e), 1502 (n), 1518 (s), 1520 (h),
or one dose of OKT8F: 1522 (,). Data from 1506 receiving three doses
of the control antibody P1.17 are shown (d). SIVmac251 RNA was be-
low the limit of detection in all LN samples (m).
Figure 5. Phenotypic changes in lymphocyte subsets before and after
administration of OKT8F. The impact of OKT8F antibody on various
cell subsets was examined by FACS® as described in Materials and Meth-
ods. As early as 1 h after antibody injection, 99% of the CD81 T cells
were depleted and 89% of CD161 NK cells were also depleted.1927 Metzner et al.
is: dT/dt 5 gT (1 2 T/Tmax), where T is the T cell count,
g is the growth or recovery rate, and Tmax is the carrying
capacity or maximum population size. Using nonlinear
least squares to fit the CD81 T cell recovery data to this
equation, we found that the two challenged macaques,
1496 and 1502, as well as 1522 had growth rates g 5 6 d21,
whereas the two other unchallenged macaques had growth
rates of 3 d21.
Analysis of tdRNA, the doubling time of SIVmac239Dnef
in plasma in days, revealed that the group A macaques had
a mean tdRNA of 0.58 d, whereas the group B macaques had
a mean tdRNA of 2.4 d (Table II). t1/2, the half-life of
SIVmac239Dnef during the period of decline from the
peak, also differed between the two groups. For group A,
these values were 0.57, 0.86, and 0.95 d (mean 5 0.79 d),
whereas for group B the half-lives were 1.24 and 2.31 d
(mean 5 1.8 d). Linear regression was done to estimate the
slope of SIV proviral DNA increase over the same period
that the viral RNA increased (Table II). In the challenged
macaques, SIV proviral DNA increased four times slower
than plasma SIV RNA, whereas in the unchallenged
macaques (1518 and 1522) the rates of RNA and DNA in-
crease were essentially identical; in 1520, the rate appeared to
be 2.5 times slower than the rate of RNA increase. How-
ever, the proviral DNA measurements for 1520 remained
below the limit of detection for 4 d after anti-CD8 antibody
administration and thus may have been increasing faster.
Discussion
In this study, rhesus macaques immunized with a live, at-
tenuated strain of SIV (SIVmac239Dnef) were treated with
an anti-CD8 mAb (OKT8F) to evaluate the effects of
CD81 T cell depletion on viral replication in vivo. Of the
five macaques receiving OKT8F antibody, 5/5 had a rapid
and sustained decline in CD81 T cells in the peripheral
blood within 1 h after antibody administration. CD81 T
cells remained low for a period of 8–10 d during which
time SIVmac239Dnef viremia increased by 1–2 logs in all
animals. Control of SIVmac239Dnef replication was tem-
porally associated with the reappearance of CD81 T cells in
the periphery. The challenge virus, SIVmac251, was not
detected in either the peripheral blood or LNs after CD81
T cell depletion, providing strong evidence that these im-
munized macaques were protected from pathogenic infec-
tion. These results provide the first direct evidence that
CD81 T cells play an important role in controlling replica-
Figure 6. The reduction in total number
of CD41 T cells and NK cells after adminis-
tration of OKT8F antibody. Variation in
the number of CD41 T cells (A and B) and
CD161 lymphocytes (C and D) over time
in four macaques receiving OKT8F anti-
body (1496 [s], 1502 [h], 1518 [n], and
1520 [e]) and the two macaques receiving
the control antibody P1.17 (1506 [d] and
1522 [j]). Only macaque 1506 received
three doses of P1.17.
Table II. Kinetics of CD81 T Cells and Viral Loads in the 
Rhesus Macaques Treated with Anti-CD8 Antibody
Macaque g* tdRNA
‡ t1/2
§ tdDNA
i Group¶ Challenged
d21 dd d
1496 6.09 0.72 0.86 2.67 A Yes
1502 5.98 0.64 0.95 2.67 A Yes
1518 3.03 1.31 1.24 1.44 B No
1520 2.98 3.47 2.31 ,8.66 B No
1522 5.85 0.39 0.57 0.38 A No
*Growth rate of CD81 T cells during recovery after depletion.
‡Doubling time of SIVmac239Dnef in plasma.
§Half-life of SIVmac239Dnef in plasma during the period of decline 
from the peak.
iDoubling time of proviral SIVmac239Dnef DNA.
¶Segregation into two groups with respect to recovery rate of CD81 T 
cells (group A, rapid recovery; group B, slow recovery).1928 Suppression of Live, Attenuated SIV In Vivo by CD81 T Cells
tion of live, attenuated SIV in a vaccine setting and support
the conclusions of several recent studies demonstrating the
effects of CD81 T cell depletion during chronic (29) and
primary (30) SIV infection.
In an earlier study, we characterized SIVmac239Dnef
replication during the acute and chronic phases of infection
in 20 rhesus macaques (3). In all animals, plasma viremia
increased in the first few weeks after infection, reaching
peak values of 105–107 RNA copies/ml, and then declined
to undetectable levels (,104 copies/ml by bDNA). In the
majority of infected macaques, plasma viremia remained
undetectable during a follow-up period of .2 yr. Here, we
examined in detail the dynamics of SIVmac239Dnef repli-
cation in six of these animals after in vivo depletion of
CD81 T cells. We found that CD81 T cell depletion re-
sults in a dramatic rise in SIVmac239Dnef plasma viremia
to levels approaching those found during acute infection,
suggesting that CD81 T cells constitute a primary immune
mechanism for control of SIVmac239Dnef replication in
vivo.
Several possible mechanisms may contribute to the con-
trol of virus replication mediated by CD81 T cells. These
include direct lysis of virus-infected target cells by SIV-spe-
cific CTLs (5) and the production of soluble factors that
suppress SIV infection (40, 41). High levels of SIV-specific
CTLs have been demonstrated in rhesus macaques chroni-
cally infected with live, attenuated SIV (22, 42). In a recent
study, CTLs against SIV Gag and Env antigens developed
within 2–4 wk after infection with SIVmac239Dnef and
persisted for up to 6 yr, even in macaques with relatively
low viral loads (22). Many of the macaques in our study
had low to undetectable viral loads in plasma and PBMCs,
yet showed a dramatic rebound in viremia after CD81 T
cell depletion, suggesting that even minimal virus replica-
tion may be sufficient to provide antigenic stimulation and
sustain potent antiviral cellular immune responses. Recent
studies have also shown that SIV replication can be inhib-
ited in vitro by soluble factors secreted by CD81 T lym-
phocytes from rhesus macaques immunized with live, at-
tenuated SIV (40, 41). Depletion of CD81 T cells in vivo
might abrogate these suppressive effects and increase plasma
viremia either by extending the life span of productively
infected cells or, alternatively, by removing the source of
inhibitory factors thereby allowing increased production of
virions.
The role of CD81 T cells in mediating protection
against pathogenic SIV challenge in macaques immunized
with live, attenuated SIV vaccines is less clear. Earlier stud-
ies failed to break protection after administering anti-CD8
antibodies in vivo (32); however, interpretation of these re-
sults is complicated by difficulties in achieving potent and
sustained depletion of CD81 T cells in the peripheral blood
and tissues. In rhesus macaques immunized with SIV-
mac239Dnef and challenged with SIVmac251, we were
unable to detect the challenge virus in peripheral blood or
LNs upon CD81 T cell depletion. It is unlikely that these
results can be explained solely on the basis of incomplete
CD81 T cell depletion, as we were able to document a
rapid and pronounced effect on replication of SIV-
mac239Dnef. Rather, failure to detect the challenge virus
may reflect eradication from the host or, alternatively, the
effects of other immune mechanism(s) that contribute to
controlling replication of wild-type SIV. With respect to
the latter, antibodies against SIV Gag and Env antigens
have been documented after immunization with SIV-
mac239Dnef (3, 10) and are maintained at high titers
throughout infection. In earlier studies, we observed in-
creasing titers of anti-SIV antibodies in macaques immu-
nized with SIVmac239Dnef, but failed to find a correlation
between protection from SIVmac251 challenge and the
presence of antibodies capable of neutralizing the challenge
virus in vitro (3). Whereas our current results do not pre-
clude the possibility that anti-SIV antibodies play a role in
mediating protection from pathogenic SIV challenge, they
do indicate that CD81 T cells are the primary mechanism
of control of live, attenuated SIV replication. To determine
whether CD81 T cells are also involved in mediating pro-
tection from pathogenic SIV infection, it would be neces-
sary to perform CD81 T cell depletion immediately before
challenge.
Similar to our previous study, we found that depletion of
CD81 T cells was accompanied by reduction in the CD41
T cells and CD161 cells in all animals receiving antibody
injections (29). One explanation for this reduction is that
OKT8F or P1.17 injection may act as a large dose of for-
eign antigen, activating numerous cell types including
CD41 T cells to later undergo activation-induced apopto-
sis. In agreement with our findings, previous studies have
shown that treatment with OKT8F results in lowering of B
cells and CD41 T cells in rhesus macaques (43). Moreover,
injection of OKT3 has also been shown to deplete non-T
cells such as B cells and NK cells in humans (44). Although
some NK cells express an a/a heterodimer of the CD8
molecule and may therefore be depleted by OKT8F, the
extent of CD161 lymphocyte depletion cannot be ac-
counted for solely by this cross-reactivity. Nor does this
explain the decline in CD161 lymphocytes observed in
macaques receiving the control antibody. These results in-
dicate that some degree of nonspecific depletion occurred
as a result of antibody injection, although the precise
mechanism of this nonspecific depletion is unknown. It is
interesting to note that not all anti-CD8 mAbs induce de-
pletion of other cell populations. In a recent report by
Schmitz et al. (30), intravenous administration of the CD8-
specific mouse–human chimeric mAb, cM-T807, to rhesus
macaques resulted in near total depletion of CD8-bearing
lymphocytes while the CD41 population remained un-
changed (30). One notable difference between the OKT8F
mAb used in this study and cM-T807 is the humanized
portion of the antibody molecule. Because OKT8F is a
murine mAb, nonspecific depletion of other cell subsets
may be due to Fc-mediated interactions. This is supported
by the observation that administration of an isotype-
matched control antibody (P1.17) also resulted in nonspe-
cific cell depletion. This effect may be minimized in rhesus
macaques by the presence of a humanized Fc domain.1929 Metzner et al.
We were particularly interested in the difference in
CD81 T cell responses in the unchallenged and challenged
macaques. The two challenged macaques, 1496 and 1502,
and the unchallenged macaque 1522 (group A) showed a
more rapid recovery of CD81 T cells and a shorter half-life
of virus during the period of decline from peak compared
with the two unchallenged rhesus macaques, 1518 and
1520 (group B), suggesting that the group A macaques had
a more vigorous CD81 T cell response. Moreover, group
B macaques did not experience a decline in SIV-
mac239Dnef until about day 14, even though the CD81 T
cells had recovered and reached close to their maximum
value by day 14. Thus, the CD81 T cells in the group B
macaques appeared less effective at controlling viremia than
those of the group A macaques. Consistent with this, we
also observed that the loss of CD81 T cells in group B did
not lead to as rapid an increase in viremia as in group A
macaques.
Possible reasons for these differences might be that the
challenge with SIVmac251 boosted the SIV-specific CD81
T cell response in macaques 1496 and 1502. Therefore,
CD81 T cell depletion in these macaques resulted in a
more decisive loss of inhibitory mechanisms responsible
for controlling of virus replication and vice versa during
the recovery of CD81 T cells. The higher viral load at
baseline in the unchallenged animal 1522 might also have
stimulated a more vigorous anti-SIV CD81 T cell re-
sponse.
Concerns over safety have long been a focal point of dis-
cussions on live, attenuated SIV vaccines. Failure to control
replication of highly attenuated strains of SIV in apparently
healthy adult and neonatal macaques has been documented
in several studies, including our own (1–3), raising doubts
as to the feasibility of pursuing this approach in humans.
While somewhat anecdotal in nature, these examples sug-
gest an inability of the immune system to effectively con-
tain ongoing viral replication. Our results indicate that
CD81 T cells provide a primary means of control over rep-
lication of SIVmac239Dnef in vivo, and raise the possibility
that pathogenic infection with live, attenuated SIV may be
associated with the inability to mount an effective cellular
immune response against the virus or, alternatively, may
represent escape from CTL control due to mutations in
immunodominant epitopes (21, 45–47). These findings un-
derscore the importance of cellular immunity in the control
of SIV replication in vivo and emphasize the need to in-
duce a strong antiviral cellular response as a component of
any candidate HIV-1 vaccine strategy.
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